X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.businesswire.com/news/home/20201001005475/en/Dr.-Reddys-Laboratories-Announces-the-Launch-of-Cinacalcet-Tablets-in-the-U.S.-Market
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213325
https://www.ema.europa.eu/en/documents/overview/cinacalcet-accordpharma-epar-medicine-overview_en.pdf
https://www.fiercepharma.com/pharma/rumors-amgen-will-buy-alexion-resurface-to-delight-investors-and-analysts
https://endpts.com/why-would-amgen-want-to-buy-alexion-analysts-call-hotly-rumored-takeover-unlikely-but-seize-the-spotlight/
https://www.fiercepharma.com/pharma/amgen-sales-slide-as-sensipar-neulasta-suffer-from-generic-and-biosim-attack
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210548
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210570
https://www.fiercepharma.com/pharma/amgen-teva-strike-sensipar-patent-deal-after-brief-generic-launch
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204377
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208971
https://www.ema.europa.eu/documents/procedural-steps-after/cinacalcet-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
https://www.pharmacompass.com/pdf/news/senispar-cinacalcet-hydrochloride-amgen-vs-emcure-pharmaceuticals-1536992435.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210207
https://www.lifesciencesipreview.com/news/amneal-obtains-non-infringement-finding-in-sensipar-case-3022?utm_source=World+IP+Review&utm_campaign=ded2754d82-LSIPR_Digital_Newsletter_31_05_2018_COPY_01&utm_medium=email&utm_term=0_d76dcadc01-ded2754d82-27561417
https://www.fiercepharma.com/pharma/could-amgen-soften-neulasta-biosimilar-blow-alexion-buy
https://www.pharmacompass.com/pdf/news/senispar-cinacalcet-hydrochloride-amgen-inc-v-accord-healthcare-inc-and-intas-pharmaceuticals-ltd-1530593445.pdf
https://www.fiercepharma.com/corporate/amgen-faces-tough-one-two-blow-as-competition-mounts-for-repatha-and-sensipar
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208915
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206125
http://www.mdmag.com/medical-news/fda-approves-2-cinacalcet-hydrochloride-generics-for-hpt-market-competition
https://www.raps.org/news-and-articles/news-articles/2018/3/fda-approves-first-generic-versions-of-amgen%E2%80%99s-sen
https://www.fiercepharma.com/legal/amgen-comes-up-short-lawsuit-against-fda-sensipar-pediatric-exclusivity-as-generics-inch
http://www.prnewswire.com/news-releases/european-commission-approves-expanded-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-children-with-end-stage-renal-disease-on-dialysis-300512398.html
http://www.prnewswire.com/news-releases/amgen-receives-positive-chmp-opinion-to-expand-use-of-mimpara-cinacalcet-for-the-treatment-of-secondary-hyperparathyroidism-in-certain-children-with-end-stage-renal-disease-on-dialysis-300479027.html
https://www.pharmacompass.com/pdf/news/sensipar-cinacalcet-hydrochloride-amgen-inc-v-piramal-healthcare-limited-1497264787.pdf
http://www.genengnews.com/gen-news-highlights/amgen-sues-to-reverse-fda-denial-of-pediatric-exclusivity-for-sensipar/81254428
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090539
http://www.pmlive.com/pharma_news/nice_set_to_back_parsabiv_for_kidney_disease_complication_1188354
http://www.multivu.com/players/English/8004551-amgen-parsabiv-fda-approval/
http://www.prnewswire.com/news-releases/european-commission-approves-parsabiv-etelcalcetide-for-the-treatment-of-secondary-hyperparathyroidism-in-adults-on-hemodialysis-300361522.html
http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/201616/anvisa+aprova+genericos+ineditos+para+hiperparatiroidismo+e+antiepiletico
https://www.pharmacompass.com/pdf/news/mylans-cinacalcet-receives-marketing-authorisation-in-eu-to-treat-secondary-hyperparathyroidism-and-reduce-hypercalcaemia-1448710183.pdf
http://www.fiercepharmamanufacturing.com/story/attix-pharmaceuticals-recalls-hundreds-apis-us/2015-04-30
Market Place
Share 
